サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：メチシリン耐性黄色ブドウ球菌（MRSA）用抗生物質の市場2022-2028
市場調査レポート
商品コード
1215733

メチシリン耐性黄色ブドウ球菌（MRSA）用抗生物質の市場2022-2028

Methicillin-Resistant Staphylococcus Aureus (MRSA) Antibiotic Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
メチシリン耐性黄色ブドウ球菌（MRSA）用抗生物質の市場2022-2028
出版日: 2023年01月14日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のMRSA抗生物質市場は、MRSAに関連する感染症の治療に関する研究開発活動やさまざまな研究の増加により、予測期間中に5.5%の大幅なCAGRで成長すると予測されています。例えば、2019年9月、デューク・ヘルス社の研究者が率いる研究により、遺伝的傾向が、人が抗生物質耐性スタフ感染症をうまく撃退できる可能性を高めると思われることが示されました。この発見は、一部の人が持続的なメチシリン耐性黄色ブドウ球菌（MRSA）感染症にかかりやすい遺伝的要因に重要な洞察を加え、より良い治療法の開発につながる可能性があります。また、この研究は、MRSA感染者が血流感染を解決するのをサポートすると思われる遺伝子変異の強い証拠を示しています。さらに、Daptomycin、Vancomycinなどの先進的な薬剤の開発にメーカーが注力していることも、MRSA治療のための市場成長を後押ししています。

世界のMRSA抗生物質市場は、治療タイプ、流通チャネルに基づいて区分されます。治療タイプに基づいて、市場はバンコマイシン、テトラサイクリン、リネゾリド、ダプトマイシン、リポペプチドに細分化されます。流通チャネルに基づき、市場はオンライン病院薬局と小売薬局にサブセグメント化されます。上記のセグメントのうち、テトラサイクリンは、それが細菌の30Sリボソームに可逆的に結合することにより、細菌のタンパク質合成を防ぐowing市場にも影響を与える別の薬剤です。テトラサイクリン系抗菌薬は、グラム陽性菌とグラム陰性菌に対して作用します。

市場は、地理的に次のように区分されます。北米、欧州、アジア太平洋地域、その他の世界の地域です。アジア太平洋地域は、予測期間中に最も速い速度で成長することが予想されます。これは、中国とインドに膨大な患者プールがあることと、インドで抗生物質の消費が制御されていないことが、アジア太平洋地域のMRSA抗生物質市場の成長を促進すると推定されるためです。

目次

第1章 レポート概要

  • 現在の産業分析と成長性の展望
  • COVID-19が世界のMRSA抗生物質市場に与える影響
  • 世界のMRSA抗生物質市場の回復シナリオ
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場の概要とインサイト

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • レコメンデーション
    • まとめ

第3章 競合情勢

  • Merck Group.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Olon Active Pharmaceutical
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Pfizer Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Viatris Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Eli Lilly and Co.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析
  • COVID-19がキープレイヤーに与える影響

第4章 市場セグメンテーション

  • MRSA抗生物質の世界市場：治療タイプ別
    • バンコマイシン
    • テトラサイクリン
    • リネゾリド
    • ダプトマイシン
    • リポペプチド
  • MRSA抗生物質の世界市場：流通チャネル別
    • オンライン
    • 病院内薬局
    • 小売店

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Allergan Inc.
  • Baxter International Inc.
  • Cumberland Pharmaceuticals Inc.
  • Debiopharm International
  • Fresenius Kabi AG
  • Innovation Pharmaceuticals Inc.
  • Melinta therapeutics Inc.
  • Nabriva Therapeutics Plc.
  • North China Pharmaceutical Group Corp.
  • Novartis International AG
  • Paratek Pharmaceuticals Inc.
  • Sanofi-Aventis Groupe
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma Inc.
  • Xellia Pharmaceuticals ApS
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zhejiang Medicine Co., Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL VANCOMYCIN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL TETRACYCLINES MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL LINEZOLID MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL DAPTOMYCIN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL LIPOPEPTIDE MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 8. GLOBAL MRSA ANTIBIOTIC BY ONLINE DISTRIBUTION CHANNEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL MRSA ANTIBIOTIC BY HOSPITAL PHARMACIES DISTRIBUTION CHANNEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL MRSA ANTIBIOTIC BY RETAIL PHARMACIES DISTRIBUTION CHANNEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 15. EUROPEAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL MRSA ANTIBIOTIC MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL MRSA ANTIBIOTIC MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL MRSA ANTIBIOTIC MARKET, 2022-2028 (%)
  • 4. GLOBAL MRSA ANTIBIOTIC MARKET BY TREATMENT TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL VANCOMYCIN MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL TETRACYCLINE MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL LINEZOLID MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL DAPTOMYCIN MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL LIPOPEPTIDE MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL MRSA ANTIBIOTIC MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
  • 11. GLOBAL MRSA ANTIBIOTIC BY ONLINE DISTRIBUTION CHANNEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL MRSA ANTIBIOTIC BY HOSPITAL PHARMACIES DISTRIBUTION CHANNEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL MRSA ANTIBIOTIC BY RETAIL PHARMACIES DISTRIBUTION CHANNEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK MRSA ANTIBIOTICMARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026789

Title:Global Methicillin-Resistant Staphylococcus Aureus (MRSA) antibiotic Market Size, Share & Trends Analysis Report by Treatment Type (Vancomycin, Tetracycline, Linezolid, Daptomycin, and Lipopeptide), and by Distribution Channel (Online, Hospital Pharmacies and Retail Pharmacies) Forecast 2022-2028.

The global MRSA antibiotic market is anticipated to grow at a substantial CAGR of 5.5% during the forecast period, owing to increasing research and development activities and various studies for the treatment of infections associated with MRSA. For instance, in September 2019, a study led by Duke Health researchers showed that an inherited genetic tendency appears to increase the likelihood that a person can successfully fight off antibiotic-resistant staph infections. The finding adds important insights into the genetic factors that predispose some people to persistent methicillin-resistant Staphylococcus aureus (MRSA) infections and could lead to the development of better treatment options. The study also provides strong evidence of a genetic variant that appears to support people with MRSA to resolve their bloodstream infections. Moreover, the increasing focus of manufacturers on the development of advanced drugs such as Daptomycin, and Vancomycin, among others, are also supporting the market growth for the treatment of MRSA.

The global MRSA antibiotic market is segmented based on the treatment type, and distribution channel. Based on the treatment type, the market is segmented into vancomycin, tetracycline, linezolid, daptomycin, and lipopeptide. Based on distribution channel the market is sub segmented into online hospital pharmacies and retail pharmacies. Among the above segment, tetracyclines is another drug that also impacts the market owing it prevents bacterial protein synthesis by reversibly binding to the bacterial 30S ribosomes. They act against gram-positive and gram-negative bacteria.

Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is set to grow at the fastest rate during the forecast period, owing to the huge patient pool in China and India and the uncontrolled consumption of antibiotics in India is estimated to fuel the growth of the MRSA antibiotic market in Asia Pacific.

The major companies serving the global MRSA antibiotic market include Merck Group., Olon Active Pharmaceutical, Pfizer Inc., Viatris Inc., Eli Lilly and Company, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, Melinta Therapeutics announced the commercial launch of KIMYRSA, a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections. The US food and drug administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients.

Research Methodology

The market study of the global MRSA antibiotic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global MRSA antibiotic Market Research and Analysis by Treatment Type
  • Global MRSA antibiotic Market Research and Analysis by Distribution Channel

The Report Covers:

  • Comprehensive research methodology of the global MRSA antibiotic market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global MRSA antibiotic market.
  • Insights about market determinants that are stimulating the global MRSA antibiotic market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global MRSA Antibiotic Market
  • Recovery Scenario of Global MRSA Antibiotic Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Merck Group.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Olon Active Pharmaceutical
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Viatris Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Eli Lilly and Co.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global MRSA Antibiotic Market by Treatment Type
    • 4.1.1. Vancomycin
    • 4.1.2. Tetracycline
    • 4.1.3. Linezolid
    • 4.1.4. Daptomycin
    • 4.1.5. Lipopeptide
  • 4.2. Global MRSA Antibiotic Market by Distribution Channel
    • 4.2.1. Online
    • 4.2.2. Hospital Pharmacies
    • 4.2.3. Retail Pharmacies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Allergan Inc.
  • 6.2. Baxter International Inc.
  • 6.3. Cumberland Pharmaceuticals Inc.
  • 6.4. Debiopharm International
  • 6.5. Fresenius Kabi AG
  • 6.6. Innovation Pharmaceuticals Inc.
  • 6.7. Melinta therapeutics Inc.
  • 6.8. Nabriva Therapeutics Plc.
  • 6.9. North China Pharmaceutical Group Corp.
  • 6.10. Novartis International AG
  • 6.11. Paratek Pharmaceuticals Inc.
  • 6.12. Sanofi-Aventis Groupe
  • 6.13. Teva Pharmaceutical Industries Ltd.
  • 6.14. Theravance Biopharma Inc.
  • 6.15. Xellia Pharmaceuticals ApS
  • 6.16. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 6.17. Zhejiang Medicine Co., Ltd.